Comparative Pricing of Branded Tenofovir Alafenamide–Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate–Emtricitabine for HIV Preexposure Prophylaxis
Authors: Moupali Das, Jie Ting, Sanatan Shreay, Staci Bush
Journal: Annals of Internal Medicine (2020)

Letters15 September 2020Comparative Pricing of Branded Tenofovir Alafenamide–Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate–Emtricitabine for HIV Preexposure ProphylaxisMoupali Das, MD, MPH, Jie Ting, PhD, Sanatan Shreay, PhD, and Staci Bush, PA-CMoupali Das, MD, MPHGilead Sciences, Foster City, California (M.D., J.T., S.S., S.B.)Search for more papers by this author, Jie Ting, PhDGilead Sciences, Foster City, California (M.D., J.T., S.S., S.B.)Search for more papers by this author, Sanatan Shreay, PhDGilead Sciences, Foster City, California (M.D., J.T., S.S., S.B.)Search for more papers by this author, and Staci Bush, PA-CGilead Sciences, Foster City, California (M.D., J.T., S.S., S.B.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L20-0692 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In a recent analysis, Walensky and colleagues (1) compared tenofovir alafenamide–emtricitabine (F/TAF) with hypothetically priced generic tenofovir disoproxil fumarate–emtricitabine (F/TDF) for HIV preexposure prophylaxis. They concluded that F/TAF would not be cost-effective compared with the hypothetically priced generic F/TDF. We disagree with this conclusion for several reasons.First, we believe that economic evaluations should consider societal and patient perspectives in order to comprehensively reflect an intervention's value. Such perspectives are completely missing from Walensky and colleagues' analysis.Second, their analysis used a 5-year time horizon. This period is insufficient to capture meaningful differences in long-term outcomes between ...References1. Walensky RP, Horn T, McCann NC, et al. Comparative pricing of branded tenofovir alafenamide-emtricitabine relative to generic tenofovir disoproxil fumarate-emtricitabine for HIV preexposure prophylaxis. A cost-effectiveness analysis. Ann Intern Med. 2020;172:583-590. [PMID: 32150602]. doi:10.7326/M19-3478 LinkGoogle Scholar2. Kim DD, Wilkinson CL, Pope EF, et al. The influence of time horizon on results of cost-effectiveness analyses. Expert Rev Pharmacoecon Outcomes Res. 2017;17:615-623. [PMID: 28504026] doi:10.1080/14737167.2017.1331432 CrossrefMedlineGoogle Scholar3. Havens PL, Perumean-Chaney SE, Patki A, et al. Changes in bone mass after discontinuation of preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine in young men who have sex with men: extension phase results of Adolescent Trials Network protocols 110 and 113. Clin Infect Dis. 2020;70:687-691. [PMID: 31179503] doi:10.1093/cid/ciz486 CrossrefMedlineGoogle Scholar4. Chou R, Evans C, Hoverman A, et al. Preexposure prophylaxis for the prevention of HIV infection: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2019;321:2214-2230. [PMID: 31184746] doi:10.1001/jama.2019.2591 CrossrefMedlineGoogle Scholar5. Federal Trade Commission. Authorized generic drugs: short-term effects and long-term impact: a report of the Federal Trade Commission. 2011. Accessed at www.ftc.gov/reports/authorized-generic-drugs-short-term-effects-long-term-impact-report-federal-trade-commission on 16 March 2020. Google Scholar Author, Article, and Disclosure InformationAffiliations: Gilead Sciences, Foster City, California (M.D., J.T., S.S., S.B.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L20-0692. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoComparative Pricing of Branded Tenofovir Alafenamide–Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate–Emtricitabine for HIV Preexposure Prophylaxis Rochelle P. Walensky , Tim Horn , Nicole C. McCann , Kenneth A. Freedberg , and A. David Paltiel Comparative Pricing of Branded Tenofovir Alafenamide–Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate–Emtricitabine for HIV Preexposure Prophylaxis Rochelle P. Walensky , Tim Horn , Nicole C. McCann , Kenneth A. Freedberg , and A. David Paltiel Metrics Cited byEvaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults 15 September 2020Volume 173, Issue 6Page: 506-507 ePublished: 15 September 2020 Issue Published: 15 September 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...